# NIH Reporter #1P50CA310825-01

Developing Novel Combination Immunotherapeutics for Non–Muscle-Invasive Bladder Cancer

**Recipient:** Sloan Kettering Institute for Cancer Research

**Award Amount:** $514,639.00
**Ceiling:** $514,639.00

**Awarded:** September 17, 2026

**Identifier:** 1P50CA310825-01

The project will study how dendritic cells shape antitumor immune responses in non–muscle-invasive bladder cancer and assess 2141-V11, alone and in combinations with BCG and IL-15/IL-15Rα, in preclinical models and clinical studies.

### Description

Research project investigating dendritic-cell responses to CD40 agonism, BCG, and other immunotherapies, and testing combination immunotherapeutic strategies for non–muscle-invasive bladder cancer.

[View original record](https://reporter.nih.gov/search/7RZVnLFgNEWpofIHyjL5uw/project-details/11335850)